Many aspects of cellular physiology remain unstudied in somatic stem cells, for example, there are almost no data on protein synthesis in any somatic stem cell. Here we set out to compare protein synthesis in haematopoietic stem cells (HSCs) and restricted haematopoietic progenitors. We found that the amount of protein synthesized per hour in HSCs in vivo was lower than in most other haematopoietic cells, even if we controlled for differences in cell cycle status or forced HSCs to undergo self-renewing divisions. Reduced ribosome function in Rpl24 Bst/1 mice further reduced protein synthesis in HSCs and impaired HSC function. Pten deletion increased protein synthesis in HSCs but also reduced HSC function. Rpl24 Bst/1 cell-autonomously rescued the effects of Pten deletion in HSCs; blocking the increase in protein synthesis, restoring HSC function, and delaying leukaemogenesis. Pten deficiency thus depletes HSCs and promotes leukaemia partly by increasing protein synthesis. Either increased or decreased protein synthesis impairs HSC function.
Mutations in ribosomes and other gene products that affect protein synthesis are associated with human diseases marked by haematopoietic dysfunction 1, 2 . Increased protein synthesis can promote the development and progression of certain cancers, including haematopoietic malignancies [3] [4] [5] [6] . Ribosomal defects commonly impair HSC and erythroid progenitor function [7] [8] [9] [10] [11] . However, it is not clear whether these defects reflect a catastrophic reduction in protein synthesis below the level required for cellular homeostasis or whether HSCs require highly regulated protein synthesis.
Methods for measuring protein synthesis have depended upon the incorporation of radiolabelled amino acids, amino acid analogues 12 , or puromycin [13] [14] [15] into nascent polypeptides in cultured cells. However, somatic stem cells profoundly change their properties in culture 16 necessitating the analysis of protein synthesis in rare cells in vivo. A new fluorogenic assay using O-propargyl-puromycin (OP-Puro) has been developed to image protein synthesis in vivo 17 . OP-Puro, like puromycin, is taken up by cells in vivo, entering ribosome acceptor sites and incorporating into nascent polypeptides 17 . An azide-alkyne reaction can be used to label OP-Puro fluorescently to quantitate protein synthesis in individual cells 17 . We adapted this approach to quantify protein synthesis by haematopoietic cells using flow cytometry.
HSCs synthesize less protein per hour
We administered a single intraperitoneal injection of OP-Puro (50 mg kg 21 body mass) then killed mice 1 h later and isolated bone marrow cells. We did not detect toxicity, signs of illness, changes in bone marrow cellularity, or changes in the frequencies of CD150 1 CD48 2 Lineage 2 Sca-1 1 c-kit 1 (CD150 1 CD48 2 LSK) HSCs 18 , annexin V 1 bone marrow cells, annexin V 1 HSCs, or dividing HSCs (Extended Data Fig. 1a-e ).
Bone marrow cells from OP-Puro-treated mice showed a clear increase in fluorescence relative to untreated mice (Fig. 1a) . The translation inhibitor cycloheximide profoundly blocked OP-Puro incorporation by bone marrow cells in culture (Fig. 1b) . Incorporation of the methionine analogues, L-homopropargylglycine (HPG) and L-azidohomoalanine (AHA), into bone marrow cells, common myeloid progenitors (CMPs), granulocytemacrophage progenitors (GMPs) and Gr-1 1 myeloid cells correlated with OP-Puro incorporation in culture ( Fig. 1c-f ).
HSCs incorporated less OP-Puro than most other bone marrow cells from the same mice (Fig. 1g ). This suggested that HSCs synthesize less protein per hour than most other haematopoietic progenitors. CD150 2 CD48 2 LSK multipotent progenitors (MPPs) 19 showed similar OP-Puro incorporation as HSCs (Fig. 1h) ; however, the mean rate of OP-Puro incorporation was significantly higher in unfractionated bone marrow cells, CMPs, GMPs, megakaryocyte-erythroid progenitors (MEPs), Gr-1 1 myeloid cells, B220 1 IgM 2 CD43 1 pro-B cells, B220 1 IgM 2 CD43 2 pre-B cells, B220 1 IgM 1 B cells, CD3 1 T cells, and CD71 1 Ter119 1 erythroid progenitors (Fig. 1h ). Extended Data Figure 1f -i shows markers, gating strategies and OP-Puro incorporation histograms for each cell population.
To test whether reduced OP-Puro incorporation into HSCs reflects OP-Puro efflux by the Abcg2 transporter (also known as Bcrp1) we administered OP-Puro to Abcg2-deficient mice, which lack efflux activity in HSCs 20 . Abcg2 2/2 HSCs continued to show significantly lower mean rates of OP-Puro incorporation compared to most other Abcg2 2/2 progenitors ( Fig. 2a ), similar to the lowest levels observed among bone marrow cells ( Fig. 2b) .
Differences in OP-Puro incorporation did not reflect proteasomal degradation 21 . The maximum OP-Puro signal in haematopoietic cells was 1 h after OP-Puro administration (data not shown). However, HSCs showed little decline in OP-Puro signal between 1 and 3 h after administration and had significantly less OP-Puro incorporation than any restricted progenitor at both times ( Fig. 2c ). In contrast, the OP-Puro signal was profoundly reduced 24 h after administration ( Fig. 2c ). This suggested that degradation of OP-Puro-containing polypeptides requires several hours. Consistent with this, incubation of bone marrow cells at 37 uC for 30 min did not significantly reduce OP-Puro fluorescence in any cell population relative to an aliquot of the same cells kept on ice to arrest degradation (Extended Data Fig. 2a ).
We pre-treated mice with bortezomib (1 mg kg 21 ; intravenous) to inhibit proteasome activity 22 1 h before OP-Puro administration. This significantly increased the OP-Puro signal in nearly all cell populations 24 h after OP-Puro administration (Extended Data Fig. 2b ). When we assessed OP-Puro incorporation 1 h after administration, bortezomib pre-treatment only modestly increased OP-Puro fluorescence in certain cell populations ( Fig. 2d ). Even in the presence of bortezomib, HSCs had significantly less OP-Puro fluorescence than restricted progenitors. The lower OP-Puro incorporation by HSCs seems to primarily reflect reduced protein synthesis rather than accelerated proteasomal degradation.
OP-Puro also did not affect the levels of phosphorylated 4EBP1 or eIF2a ( Fig. 2e) , key regulators of translation that can be influenced by proteotoxic stress 23, 24 . HSCs and MPPs had less phosphorylated 4EBP1 and b-actin per cell than other haematopoietic cells but similar levels of total 4EBP1. This raised the possibility that HSCs synthesize less protein as a consequence of increased 4EBP1-mediated inhibition of translation ( Fig. 2e ).
Doubling the dose of OP-Puro to 100 mg kg 21 significantly increased OP-Puro incorporation in all cell populations, but HSCs continued to have significantly lower levels than all other cell populations except MPPs (Fig. 2f ). Thus, 50 mg kg 21 OP-Puro did not significantly attenuate protein synthesis and uptake was not saturated in HSCs or most other cells.
Dividing HSCs also make less protein
Haematopoietic progenitors in the replicating phases of the cell cycle (S, G 2 and M phases; S/G 2 /M) exhibited significantly higher rates of OP-Puro incorporation than cells in G 0 and G 1 phases (G 0 /G 1 ) ( Fig. 3a, b ). Total protein was also higher in Gr-1 1 cells and bone marrow cells in S/G 2 /M than in G 0 /G 1 (Extended Data Fig. 3b ). However, HSCs and MPPs exhibited less OP-Puro incorporation than restricted progenitors even when we compared only cells in G 0 /G 1 (Fig. 3b ). We treated mice with cyclophosphamide followed by two daily injections of granulocyte colony-stimulating factor (GCSF) to induce self-renewing divisions by HSCs (Extended Data Fig. 3d ) 25 . Cyclophosphamide and GCSF also increased division by MPPs, Gr-1 1 cells and IgM 1 B cells (Extended Data Fig. 3a, e ). Each of these populations showed increased OP-Puro incorporation after cyclophosphamide and GCSF treatment ( Fig. 3c ). However, HSCs had significantly less protein synthesis compared to most restricted progenitors, irrespective of whether we compared S/G 2 /M cells (Fig. 3e ) or G 0 /G 1 cells ( Fig. 3d and Extended Data Fig. 3f , g) from mice treated with cyclophosphamide and GCSF. Differences in protein synthesis between HSCs and restricted progenitors were not fully explained by differences in cell diameter ( Fig. 3f and Extended Data Fig. 4b ), ribosomal RNA ( Fig. 3g and Extended Data Fig. 4c, d ), or total RNA content (Extended Data Figs 3c and 4e), which were similar among HSCs and lymphoid progenitors despite differences in protein synthesis.
Ribosomal mutant impairs HSC function
Rpl24 Bst/1 mice have a hypomorphic mutation in the Rpl24 ribosome subunit, reducing protein synthesis in multiple cell types by 30% in culture 3, 4, 26 . Adult Rpl24 Bst/1 mice show relatively mild phenotypes: they are 20% smaller than wild-type mice and have mild pigmentation and skeletal abnormalities 26 . These Rpl24 Bst/1 mice had normal bone marrow, spleen and thymus cellularity, blood cell counts (Extended Data Fig. 5a , b) and HSC frequency ( Fig. 4a ). Frequencies of colony-forming progenitors (Extended Data Fig. 6b ), restricted progenitors, and annexin V 1 HSCs and MPPs (Extended Data Fig. 5c -i) were also largely normal.
OP-Puro incorporation into unfractionated bone marrow cells, HSCs, GMPs and pre-B cells from Rpl24 Bst/1 mice was significantly reduced relative to wild-type cells (Fig. 4d ). In the case of HSCs from Rpl24 Bst/1 mice, OP-Puro incorporation was reduced by approximately 30% relative to control HSCs. However, Rpl24 was highly differentially expressed 
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among haematopoietic cells and some cell populations seemed to depend more than others on Rpl24 for protein synthesis (Extended Data Fig. 5j ). After transplantation into irradiated mice, Rpl24 Bst/1 bone marrow cells gave significantly lower levels of donor cell reconstitution in the myeloid-, B-and T-cell lineages relative to control donor cells ( Fig. 4e and Extended Data Fig. 5k ). We did not detect impaired homing of Rpl24 Bst/1 LSK cells to the bone marrow (Extended Data Fig. 5l ). Significantly impaired reconstitution by Rpl24 Bst/1 cells was also evident in secondary recipient mice (Fig. 4f ). After cyclophosphamide and GCSF treatment, significantly fewer Rpl24 Bst/1 HSCs were in S/G 2 /M than wild-type HSCs (Fig. 4b ). HSC frequency in the bone marrow after cyclophosphamide and GCSF treatment was two-to threefold higher in wild-type than Rpl24 Bst/1 mice (Fig. 4c ). Furthermore, colonies formed by individual Rpl24 Bst/1 HSCs in methylcellulose contained significantly fewer cells than wild-type HSC colonies (Extended Data Fig. 6c ). Rpl24 Bst/1 HSCs are thus impaired in their proliferative potential.
Some ribosomal defects can induce p53 activation and expression of its target p21 Cip1 (also known as Cdkn1a) 27 . When we compared Rpl24 Bst/1 with wild-type cells, we did not detect any difference in p53 levels among Lineage 2 haematopoietic progenitors (Extended Data Fig. 5m ) or in p21 Cip1 levels among LSK cells (Extended Data Fig. 5n ). These data are consistent with previous studies 28 indicating that p53 and p21 Cip1 are not induced in adult Rpl24 Bst/1 haematopoietic cells. Moreover, loss of a single allele of p53 did not rescue the size of colonies formed by Rpl24 Bst/1 HSCs in culture (Extended Data Fig. 6e ), even though p53 heterozygosity largely rescues developmental phenotypes in Rpl24 Bst/1 embryos 28 . HSC defects in Rpl24 Bst/1 mice are therefore not caused by increased p53 function.
Pten deletion increases protein synthesis
HSCs had phosphorylated Akt (pAkt) and pS6 levels that were similar to lymphoid progenitors but lower than myeloid progenitors ( Fig. 5a and Extended Data Fig. 4f ). We conditionally deleted Pten from adult haematopoietic cells in Mx1-Cre; Pten fl/fl mice. As shown previously [29] [30] [31] [32] [33] , Pten deletion strongly increased pAKT and pS6 levels in bone marrow cells ( Fig. 5a ) and in HSCs and MPPs (Fig. 5d ). Consistent with this, we observed an approximately 30% increase in protein synthesis in Pten-deficient relative to control HSCs (P , 0.01; Fig. 5b,c) .
HSCs are depleted after Pten deletion, even after transplantation into wild-type recipients that never develop leukaemia, by a mechanism that depends on cell-autonomous mTORC1 and mTORC2 activation [29] [30] [31] [32] . We examined OP-Puro incorporation into HSCs from Mx1-Cre; Rictor fl/fl mice, Mx1-Cre; Rictor fl/fl ; Pten fl/fl mice, and Mx1-Cre; Pten fl/fl mice. Rictor deletion (which inactivates mTORC2) had no effect on the rate of protein synthesis in otherwise wild-type HSCs ( Fig. 5c and Extended Data Fig. 6g ), consistent with the normal reconstituting capacity of Rictordeficient HSCs 30 . However, Rictor deficiency significantly reduced protein synthesis in Pten-deficient HSCs to normal levels ( Fig. 5c and Extended Data Fig. 6g ). The ability of Rictor deletion to rescue both protein synthesis and HSC function after Pten deletion 30 suggested that Pten deletion depletes HSCs partly by cell-autonomously increasing protein synthesis. Rapamycin treatment, which also prevents HSC depletion after Pten deletion 31, 32 , also blocked the increase in protein synthesis in Pten-deficient HSCs (data not shown).
HSCs from Mx1-Cre; Pten fl/fl ; Rpl24 Bst/1 mice had significantly less protein synthesis than HSCs from Mx1-Cre; Pten fl/fl mice (Fig. 5b, c) . Although ribosomes can promote mTORC2 signalling 34 , Rpl24 Bst/1 did not reduce levels of pAKT, pGSK3b, pS6, or p4EBP1 in HSCs and MPPs (Fig. 5d ), suggesting Rpl24 Bst/1 did not reduce mTORC1 or mTORC2 signalling. In fact, Mx1-Cre; Pten fl/fl ; Rpl24 Bst/1 HSCs and MPPs had slightly increased levels of pS6 and p4EBP1 relative to Pten-deficient HSCs and MPPs, but this would be expected to further increase protein synthesis rather than reducing it. This suggested that Rpl24 Bst/1 acted downstream of the PI3-kinase pathway to block the increase in protein synthesis in HSCs after Pten deletion, raising the question of whether Rpl24 Bst/1 could also block leukaemogenesis or HSC depletion.
Rpl24 Bst suppresses leukaemogenesis
Conditional deletion of Pten in haematopoietic cells leads to a myeloproliferative disorder (MPD) and T-cell acute lymphoblastic leukaemia (T-ALL) 31, 33, 35 . Increased protein synthesis promotes some haematopoietic malignancies, including T-cell leukaemias 3, 4, 6, 36 . Two weeks after polyinosinic-polycytidylic acid (pIpC) administration, Mx1-Cre; Pten fl/fl mice showed significantly increased spleen and thymus cellularity (Fig. 5e, f and Extended Data Fig. 6h, i) , consistent with the induction of MPD and T-ALL 31, 33, 35 . Mx1-Cre; Pten fl/fl ; Rpl24 Bst/1 mice exhibited normal spleen and thymus cellularity (Fig. 5e, f and Extended Data Fig. 6h, i ), suggesting that reduced ribosome function impaired the development of MPD and T-ALL after Pten deletion.
To compare MPD and T-ALL development we transplanted 2 3 10 6 bone marrow cells from each genetic background into irradiated mice then treated with pIpC 4 weeks later. Recipients of Mx1-Cre; Pten fl/fl ; Rpl24 Bst/1 haematopoietic cells lived significantly longer than recipients of Mx1-Cre; Pten fl/fl haematopoietic cells (Fig. 5g ). We confirmed by PCR that the donor cells had completely excised Pten (data not shown). When ill recipients of cells of either genotype were killed, they showed splenomegaly, thymomegaly and histological signs of MPD and T-ALL (Extended Data Fig. 6k ). Rpl24 Bst/1 therefore significantly delayed (P , 0.001; Fig. 5g ), but did not entirely prevent, MPD and T-ALL after Pten deletion. It is unclear whether Rpl24 Bst/1 impairs leukaemogenesis by acting within HSCs or within other haematopoietic cells.
Pten deletion mobilizes HSCs to the spleen 29, 30 . Rpl24 Bst/1 blocked this effect, restoring normal HSC numbers in spleens of Mx1-Cre; Pten fl/fl ; Rpl24 Bst/1 mice (Extended Data Fig. 6j ).
Rpl24 Bst rescues Pten-deficient HSCs
We performed long-term reconstitution assays in which we transplanted 10 CD150 1 CD48 2 LSK HSCs from wild-type, Mx1-Cre; Pten fl/fl , Rpl24 Bst/1 , or Mx1-Cre; Pten fl/fl ; Rpl24 Bst/1 mice along with 300,000 wild-type bone marrow cells into irradiated wild-type mice. As expected, most (15 of 18) recipients of wild-type HSCs but no (0 of 12) recipients of Ptendeficient HSCs showed long-term multilineage reconstitution by donor cells (Fig. 5h, i) . Relative to control HSCs, Rpl24 Bst/1 HSCs gave lower levels of donor-cell reconstitution in all lineages (Fig. 5h ) and a somewhat lower fraction of recipients showed long-term multilineage reconstitution (10 of 19; Fig. 5i ), although these differences were not statistically significant. Relative to Pten-deficient HSCs, Mx1-Cre; Pten fl/fl ; Rpl24 Bst/1 compound mutant HSCs gave significantly higher levels of reconstitution and a significantly higher percentage of recipients showed long-term multilineage reconstitution by donor cells (Fig. 5h, i) . Reconstitution by Mx1-Cre; Pten fl/fl ; Rpl24 Bst/1 HSCs was statistically indistinguishable from wild-type HSCs in all lineages except the B lineage (Pten deficiency impairs B-lineage progenitors independent of its effects on HSCs 33 ; Fig. 5h ). We confirmed by PCR that the donor cells had completely excised Pten (data not shown). This demonstrates that reducing protein synthesis restores the ability of Pten-deficient HSCs to give long-term multilineage reconstitution. Secondary transplantation of 3 3 10 6 bone marrow cells from primary recipients with long-term multilineage reconstitution in Fig. 5h produced significantly less donor cell reconstitution and long-term multilineage reconstitution among recipients of Rpl24 Bst/1 compared to control HSCs (Fig. 5j, k) . Secondary recipients of Mx1-Cre; Pten fl/fl ; Rpl24 Bst/1 compound mutant HSCs also showed significantly less donor cell reconstitution and long-term multilineage reconstitution compared to control HSCs. Rpl24 Bst/1 thus restored long-term multilineage reconstituting potential to Pten-deficient HSCs but did not fully restore wildtype function. Pten deficiency thus impairs HSC function, in part by increasing protein synthesis.
To test MPP function we competitively transplanted 100 donor CD150 2 CD48 2 LSK MPPs 19 from Mx-1-Cre; Pten fl/fl , Rpl24 Bst/1 , or control mice into irradiated recipients. There was a trend towards lower reconstitution by Rpl24 Bst/1 MPPs and Pten-deficient MPPs relative to control MPPs but the differences were not statistically significant RESEARCH ARTICLE (Extended Data Fig. 7a, b ). Neither Rpl24 Bst/1 nor Pten deletion significantly affected the percentage of bone marrow cells that formed colonies or the cellularity of those colonies (Extended Data Fig. 6b, d) . Thus, we have not detected clear effects of Rpl24 Bst/1 or Pten deletion on the proliferative potential of MPPs or restricted progenitors, suggesting that they are not as sensitive as HSCs to changes in protein synthesis, although it remains possible that they are also impaired by changes in protein synthesis.
DISCUSSION
When we added HSCs to culture, OP-Puro incorporation increased dramatically (data not shown). This raises the possibility that the failure to maintain HSCs sustainably under any known culture conditions 37 may reflect a limitation imposed by increased protein synthesis. Consistent with this, rapamycin promotes HSC maintenance in culture 38 , although it remains to be determined whether rapamycin attenuates the increase in protein synthesis in cultured HSCs.
Low rates of protein synthesis may be essential for maintaining metabolic homeostasis in HSCs and potentially in other kinds of somatic stem cells. Changes in protein synthesis may cause undesirable changes in the quality and/or content of the proteome, such as due to misfolding. There may also be changes in the translation of certain subsets of transcripts (potentially including key HSC regulators) when protein synthesis increases, similar to what occurs in cancer cells 5 . HSCs were transplanted along with 3 3 10 5 recipient bone marrow cells into irradiated recipients. Donor-cell engraftment (h) and fraction of recipients that showed long-term multilineage reconstitution (i; 3 experiments). j, k, Donor-cell engraftment (j) and the fraction of secondary recipients that showed long-term multilineage reconstitution (k) after transplantation of 3 3 10 6 bone marrow cells from primary recipients in h (n 5 4 donors per genotype). All data represent mean 6 s.d. Differences among genotypes (c, f, h) were assessed with a one-way ANOVA followed by Dunnett's test for multiple comparisons. Statistical significance was assessed by log-rank test (g), chi-squared tests followed by Tukey's t-tests for pairwise comparisons (i, k), or a one-way ANOVA followed by Tukey's t-tests for multiple comparisons (j). Significance was expressed relative to wild-type ({P , 0.05, {{P , 0.01, {{{P , 0.001) or Pten-deficient cells (*P , 0.05, **P , 0.01, ***P , 0.001).
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Embryonic stem cells have high proteasome activity and proteasome activity increases both embryonic-stem-cell maintenance and Caenorhabditis elegans lifespan 39, 40 . Rapamycin treatment, and mutations that reduce mTOR signalling, also increase lifespan (see citations in ref. 41 ) and would be predicted to reduce protein synthesis. In the context of these results, our observations raise the possibility that reduced protein synthesis and/or increased proteasome activity is required to maintain certain long-lived somatic cells in addition to increasing organismal lifespan.
METHODS SUMMARY
For in vivo quantification of protein synthesis, OP-Puro (50 mg kg 21 ; pH 6.4-6.6 in PBS; Medchem Source) was injected intraperitoneally. Unless otherwise indicated, bone marrow was collected 1 h later and 3 3 10 6 cells were stained with antibodies against cell surface markers, fixed in 1% paraformaldehyde, and permeabilized in PBS with 3% fetal bovine serum and 0.1% saponin, as described in the Methods. OP-Puro was detected by performing an azide-alkyne cycloaddition with the Click-iT Cell Reaction Buffer Kit (Life Technologies), and analysed by flow cytometry as described in the Methods. 'Relative rates of protein synthesis' were calculated by normalizing OP-Puro signals to bone marrow after subtracting background fluorescence. 'Mean OP-Puro fluorescence' reflected absolute fluorescence values for each cell population from multiple experiments.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. 45 ) mutant mice have been described previously. These mice were all backcrossed for at least eight generations onto a C57BL background, with the exception of Abcg2 2/2 mice, which were on an FVB.129 N7 background (Taconic). C57BL/Ka-Thy-1.1 (CD45.2) and C57BL/Ka-Thy-1.2 (CD45.1) mice were used in transplantation experiments. Both male and female mice were used in all studies. Expression of Mx1-Cre was induced by three or four intraperitoneal injections of 10 mg pIpC (GE Healthcare) administered every other day, beginning at approximately 6 weeks of age. For cyclophosphamide and GCSF experiments, 4 mg of cyclophosphamide (Baxter) was administered by intraperitoneal injection on day 0, and 5 mg of GCSF (Neupogen; Amgen) was administered by subcutaneous injection on days 1 and 2. Mice were analysed on day 3. All mice were housed in the Unit for Laboratory Animal Medicine at the University of Michigan, where breeding for these studies was initiated, or in the Animal Resource Center at the University of Texas Southwestern Medical Center, where these studies were performed. All protocols were approved by the University of Michigan Committee on the Use and Care of Animals and by the University of Texas Southwestern Institutional Animal Care and Use Committee. Measurement of protein synthesis. For in vitro analysis 10 3 -10 4 bone marrow or sorted cells were plated in 100 ml of methionine-free Dulbecco's Modified Eagle's Medium (Sigma) supplemented with 200 mM L-cysteine (Sigma), 50 mM 2-mercaptoethanol (Sigma), 1 mM L-glutamine (Gibco) and 0.1% bovine serum albumin (BSA; Sigma). For analysis of HPG and AHA incorporation, cells were pre-cultured for 45 min to deplete endogenous methionine. For OP-Puro, the medium was supplemented with 1 mM L-methionine (Sigma). HPG (Life Technologies; 1 mM final concentration), AHA (Life Technologies; 1 mM final concentration) or OP-Puro (Medchem Source; 50 mM final concentration) were added to the culture medium for 1 h (HPG and OP-Puro) or 2.5 h (AHA), then cells were removed from wells and washed twice in Ca 21 -and Mg 21 -free phosphate buffered saline (PBS). Cells were fixed in 0.5 ml of 1% paraformaldehyde (Affymetrix) in PBS for 15 min on ice. Cells were washed in PBS, then permeabilized in 200 ml PBS supplemented with 3% fetal bovine serum (Sigma) and 0.1% saponin (Sigma) for 5 min at room temperature (20-25 uC) . The azide-alkyne cycloaddition was performed using the Click-iT Cell Reaction Buffer Kit (Life Technologies) and azide conjugated to Alexa Fluor 488 or Alexa Fluor 555 (Life Technologies) at 5 mM final concentration. After the 30-min reaction, the cells were washed twice in PBS supplemented with 3% fetal bovine serum and 0.1% saponin, then resuspended in PBS supplemented with 49,6-diamidino-2-phenylindole (DAPI; 4 mg ml 21 final concentration) and analysed by flow cytometry. To inhibit OP-Puro, HPG or AHA incorporation, cycloheximide (Sigma) was added 30 min before OP-Puro, HPG or AHA at a final concentration of 100 mg ml 21 . All cultures were incubated at 37 uC in 6.5% CO 2 and constant humidity.
For in vivo analysis, OP-Puro (50 mg kg 21 body mass; pH 6.4-6.6 in PBS) was injected intraperitoneally. One hour later mice were euthanized, unless indicated otherwise. Bone marrow was collected, and 3 3 10 6 cells were stained with combinations of antibodies against cell-surface markers as described below. After washing, the cells were fixed, permeabilized, and the azide-alkyne cycloaddition was performed as described above. 'Relative rates of protein synthesis' were calculated by normalizing OP-Puro signals to whole bone marrow after subtracting autofluorescence background. 'Mean OP-Puro fluorescence' reflected absolute fluorescence values for each cell population from multiple independent experiments.
To assess the effect of proteasome activity on OP-Puro incorporation mice were administered an intravenous injection of bortezomib (Cell Signaling; 1 mg kg 21 body mass) 1 h before OP-Puro administration. OP-Puro incorporation was assessed as described above 1 h later unless indicated otherwise. Flow cytometry and cell isolation. Bone marrow cells were isolated by flushing the long bones (femurs and tibias) or by crushing the long bones, vertebrae and pelvic bones with a mortar and pestle in Ca 21 -and Mg 21 -free Hank's buffered salt solution (HBSS; Gibco) supplemented with 2% heat-inactivated bovine serum (Gibco). Spleens and thymuses were prepared by crushing tissues between frosted slides. All cells were filtered through a 40-mm cell strainer to obtain single cell suspensions. Cell number and viability were assessed by a Vi-CELL cell viability analyser (Beckman Coulter) or by counting with a hemocytometer.
For flow cytometric analysis and isolation of specific haematopoietic progenitors, cells were incubated with combinations of antibodies to the following cell-surface markers, conjugated to FITC, PE, PerCP-Cy5.5, Cy5, APC, PE-Cy7, eFluor 660, Alexa Fluor 700, APC-eFluor 780 or biotin (antibodies are given in brackets in the following list): CD2 (RM2-5), CD3e (17A2), CD4 (GK1.5), CD5 (53-7.3), CD8a (53-6.7), CD11b (M1/70), CD16/32 (FcYRII/III; 93), CD24 (M1/69), CD25 (PC61.5), CD34 (RAM34), CD43 (1B11), CD44 (IM7), CD45.1 (A20), CD45.2 (104), CD45R (B220; RA3-6B2), CD48 (HM48-1), CD71 (C2), CD117 (cKit; 2B8), CD127 (IL7Ra; A7R34), CD138 (281-2), CD150 (TC15-12F12.2), Ter119 (TER-119), Sca-1 (D7, E13-161.7), Gr-1 (RB6-8C5) and IgM (II/41). For isolation of HSCs and MPPs, Lineage markers included CD3, CD5, CD8, B220, Gr-1 and Ter119. For isolation of CMPs, GMPs and MEPs, these Lineage markers were supplemented with additional antibodies against CD4 and CD11b.
Biotinylated antibodies were visualized by incubation with PE-Cy7 or APC-Alexa Fluor 750 conjugated streptavidin. All reagents were acquired from BD Biosciences, eBiosciences, or BioLegend. All incubations were for approximately 30 min on ice. HSCs, MPPs, CD34 1 CD16/32 low CD127 2 Lineage 2 Sca-1 2 c-kit 1 CMPs (ref. 46 ), CD34 1 CD16/32 high CD127 2 Lineage 2 Sca-1c-kit 1 GMPs (ref. 46) , and CD34 2 CD16/32 2/low CD127 2 Lineage -Sca-1 2 c-kit 1 MEPs (ref. 46) were sometimes preenriched by selecting c-kit 1 cells using paramagnetic microbeads and an autoMACS magnetic separator (Miltenyi Biotec).
Non-viable cells were excluded from sorts and analyses using DAPI (49,6diamidino-2-phenylindole). Apoptotic cells were identified using APC annexin V (BD Biosciences). Data acquisition and cell sorting were performed on a FACSAria flow cytometer (BD Biosciences). All sorted fractions were double sorted to ensure high purity. Data were analysed by FACSDiva (BD Biosciences) or FlowJo (Tree Star) software. Long-term competitive repopulation assay. Adult recipient mice (CD45.1) were administered a minimum lethal dose of radiation using an XRAD 320 X-ray irradiator (Precision X-Ray) to deliver two doses of 540 rad (1,080 rad in total) at least 3 h apart. Cells were injected into the retro-orbital venous sinus of anaesthetized recipients. For competitive bone marrow transplants 5 3 10 5 donor and 5 3 10 5 recipient cells were transplanted. For HSC transplants 10 donor CD150 1 CD48 2 Lineage 2 Sca-1 1 c-kit 1 HSCs and 3 3 10 5 recipient bone marrow cells were transplanted. Blood was obtained from the tail veins of recipient mice every 4 weeks for at least 16 weeks after transplantation. For MPP transplants 100 donor CD150 2 CD48 2 Lineage 2 Sca-1 1 c-kit 1 MPPs and 3 3 10 5 recipient bone marrow cells were transplanted. Blood was obtained from the tail veins of recipient mice 3, 5 and 7 weeks after transplantation. Red blood cells were lysed with ammonium chloride potassium buffer. The remaining cells were stained with antibodies against CD45.2, CD45.1, CD45R (B220), CD11b, CD3 and Gr-1 to assess donor-cell engraftment. Mice that died or developed obvious haematopoietic neoplasms were omitted from the analyses. For secondary transplants, 3 3 10 6 bone marrow cells collected from primary recipients were transplanted non-competitively into irradiated recipient mice. Primary recipients used for secondary transplantation had long-term multilineage reconstitution by donor cells and levels of donor-cell reconstitution that were typical (closest to mean values) for the treatments from which they originated. For survival studies in Fig. 5 , irradiated mice were transplanted with 2 3 10 6 bone marrow cells of each genotype and pIpC was administered 4 weeks later to delete Pten. Three to four donors per genotype were used with 5 to 10 recipients per donor. Mice were euthanized when they appeared moribund. Western blot analysis. Equal numbers of cells from each stem or progenitor population (unless indicated otherwise) were sorted into, or resuspended in, trichloracetic acid (TCA, Sigma). The final concentration was adjusted to 10% TCA. Extracts were incubated on ice for at least 15 min and centrifuged at 16,100g at 4 uC for 15 min. Precipitates were washed in acetone twice and dried. The pellets were solubilized in 9 M urea, 2% Triton X-100, and 1% DTT. LDS loading buffer (Life Technologies) was added and the pellet was heated at 70 uC for 10 min. Samples were separated on Bis-Trispolyacrylamide gels (Life Technologies) and transferred to PVDF membranes (Millipore). Western blot analyses were performed according to the protocol from Cell Signaling Technologies and blots were developed with the SuperSignal West Femto chemiluminescence kit (Thermo Scientific). Blots were stripped with 1% SDS, 25 mM glycine (pH 2) before re-probing. The following primary antibodies were used for western blot analyses (obtained from Cell Signaling Technologies unless indicated otherwise): phos-Akt (Ser473; D9E), AKT (C67E7), phos-S6 (Ser240/244; polyclonal), S6 (5G10), phos-4E-BP1 (Thr37/ 46; 236B4), 4E-BP1 (polyclonal), phos-eIF2a (Ser51; polyclonal), eIF2a (D7D3), phos-GSK3b (Ser9; D85E12), b-actin (AC-74; Sigma), p53 (cm5p; Leica), p21 Cip1 (F-5; Santa Cruz) and Rpl24 (polyclonal; Abcam). For p21 Cip1 , the membranes were treated with the SuperSignal Western Blot Enhancer (Thermo Scientific). Band intensity was quantified with ImageJ software. Methylcellulose cultures. Two-hundred live bone marrow cells or single CD150 1 CD48 2 LSK cells were sorted per well of a 96-well plate containing methylcellulose culture medium (M3434, StemCell Technologies) and incubated at 37 uC in 6.5% CO 2 and constant humidity. Colony formation was assessed 14 days after plating, except for data shown in Extended Data Fig. 6e , in which colonies were assessed 15 days after plating. Colony size was assessed by picking individual colonies with a pipette under the microscope, washing the cells in PBS, and counting live cells by Trypan blue exclusion on a hemocytometer. Cell size. The average diameter of sorted cells was measured by sorting cells into flat-bottom 96-well plates and analysing micrographs with ImageJ software.
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RNA content. From each haematopoietic-cell population, 15,000 cells were sorted into RLT Plus buffer (Qiagen) supplemented with 2-mercaptoethanol. RNA from each sample was extracted with the RNeasy micro plus kit (Qiagen) into 14 ml of water. Two microlitres of each sample were analysed in duplicate for 18S rRNA, 28S rRNA and total RNA concentration using an Agilent RNA 6000 Pico kit and a Bioanalyzer (Agilent) at the University of Texas Southwestern Genomics and Microarray Core. Protein content. From each population, 50,000 cells were sorted into PBS. G 0 /G 1 cells were distinguished from S/G 2 /M cells based on DNA content using Hoechst 33342 (Sigma) staining of live cells. Cells were spun down and resuspended in 20 ml of RIPA buffer (Pierce) supplemented with complete protease inhibitor (Roche) and rotated at 4 uC for 30 min. Lysates were spun down at 16,100g at 4 uC for 15 min. The protein content in the supernatant was assessed with the BCA assay (Pierce). Statistical methods. In all cases, multiple independent experiments were performed on different days to verify the reproducibility of experimental findings. Group data are always represented by mean 6 standard deviation. The numbers of experiments noted in figure legends reflect independent experiments performed on different days.
To test statistical significance between two samples, two-tailed Student's t-tests were used. When multiple samples were compared, statistical significance was assessed using a one-way ANOVA or a repeated-measures one-way ANOVA (when comparing multiple time points or populations from the same mouse) followed by Dunnett's test for multiple comparisons. When multiple samples were each compared to one another, statistical significance was assessed using a one-way ANOVA followed by Tukey's t-tests for multiple comparisons. Statistical significance comparing overall numbers of mice with long-term multilineage reconsitution was assessed either by a Fisher's exact test (Fig. 4f ) or by chi-squared tests followed by Tukey's t-tests for pairwise comparisons (Fig. 5i, k) . Statistical significance with respect to differences in survival ( Fig. 5g ) was calculated using a log-rank test. The specific type of test used for each figure panel is described in the figure legends.
For normalized protein synthesis rates and normalized messenger RNA expression, means were calculated and statistical tests were performed using log 10 -transformed data and then means were back-transformed to prevent data skewing.
No randomization or blinding was used in any experiments. The only mice excluded from any experiment were those that developed leukaemia after transplantation in Fig. 5h , i. As the purpose of this experiment was to compare the reconstituting capacity of normal HSCs, the presence of leukaemia in a minority of recipient mice was a confounding factor that had the potential to inappropriately skew the results; therefore, the experiment was initiated with the intention of excluding data from any mouse that died during the experiment. We excluded 0 to 4 mice per treatment.
In the case of measurements in which variation among experiments tends to be low (for example, HSC frequency) we generally examined 3 to 6 mice. In the case of measurements in which variation among experiments tends to be higher (for example, reconstitution assays) we examined larger numbers of mice (.10). In the case of assays to assess protein synthesis, there were no historical data on which to base sample sizes, and we therefore performed multiple independent experiments with multiple biological replicates to ensure the reproducibility of our findings.
